These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 27890172)
1. Opportunistic Infections in Biological Therapy, Risk and Prevention. Bryant PA; Baddley JW Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172 [TBL] [Abstract][Full Text] [Related]
2. Infection Risk and Safety of Corticosteroid Use. Youssef J; Novosad SA; Winthrop KL Rheum Dis Clin North Am; 2016 Feb; 42(1):157-76, ix-x. PubMed ID: 26611557 [TBL] [Abstract][Full Text] [Related]
3. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Mok CC; Chan KY; Lee KL; Tam LS; Lee KW; Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315 [TBL] [Abstract][Full Text] [Related]
4. Serious infections associated with anticytokine therapies in the rheumatic diseases. Giles JT; Bathon JM J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118 [TBL] [Abstract][Full Text] [Related]
5. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India. Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281 [TBL] [Abstract][Full Text] [Related]
8. [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 3. Opportunistic infections]. Sumida K; Ubara Y Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2631-8. PubMed ID: 24400544 [No Abstract] [Full Text] [Related]
9. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}. Winthrop KL Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382 [No Abstract] [Full Text] [Related]
10. Infection and anti-tumor necrosis factor-alpha therapy. Zandman-Goddard G Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109 [No Abstract] [Full Text] [Related]
11. Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Bruce ES; Kearsley-Fleet L; Watson KD; Symmons DP; Hyrich KL Rheumatology (Oxford); 2016 Jul; 55(7):1336-7. PubMed ID: 27118877 [No Abstract] [Full Text] [Related]
12. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045 [TBL] [Abstract][Full Text] [Related]
13. Mycobacterium chelonae infection associated with adalimumab therapy. Díaz F; Urkijo JC; Mendoza F; de la Viuda JM; Blanco M; Unzurrunzaga A; Ayarza R Scand J Rheumatol; 2008; 37(2):159-60. PubMed ID: 18415777 [No Abstract] [Full Text] [Related]
16. Serious Opportunistic Lower Respiratory Tract Infections in Pediatric Rheumatic Diseases During Treatment With Biologics. Ogstrup AK; Spannow AH; Holm M; Rubak S; Veirum JE; Glerup M; Herlin T J Clin Rheumatol; 2021 Dec; 27(8S):S387-S391. PubMed ID: 32694355 [No Abstract] [Full Text] [Related]
17. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Winthrop KL Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599 [TBL] [Abstract][Full Text] [Related]
19. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety. Al-Mayouf SM; Alenazi A; AlJasser H Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661 [TBL] [Abstract][Full Text] [Related]
20. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections. Clemente D; Cuadros EN; Lovillo MC; Hernández JC; Martín SG; Silveira LF; Cruz MJL; Tagarro A; Rueda RMA; López López A; Aritziturri MS; Calvo C Eur J Pediatr; 2024 Feb; 183(2):915-927. PubMed ID: 38047962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]